MedTrace Logo

Benign Prostatic Hyperplasia and Ischemic Heart DIsease

NCT03856242 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2019-02-27

No results posted yet for this study

Summary

To examine the dynamics of 24 - hours ECG monitoring parameters (Holter monitoring) in patients with ischaemic heart disease (IHD) before and after treatment of voiding dysfunctions resulted from benign prostatic hyperplasia (BPH) with the indications for either conservative or operative treatment.

A total of eighty-three 57-to-81-year-old (mean age 70.4±5.75 years) patients with BPH and accompanying IHD were examined at the Institute of Urology and Human Reproductive Health and Clinic of Cardiology of the Sechenov University.

Conditions

  • Ischaemic Heart Disease (IHD)
  • Benign Prostatic Hyperplasia (BPH)
  • Lower Urinary Tract Symptoms (LUTS)

Interventions

DRUG

Tamsulosin Oral Capsule

Tamsulosin Oral Capsule - alpha-1-adrenoblocker for treatment LUTS/BPH 0.4 mg

PROCEDURE

TURP

Routine transurethral prostatic resection

Sponsors & Collaborators

  • I.M. Sechenov First Moscow State Medical University

    lead OTHER

Principal Investigators

  • Andrey Z Vinarov, PhD · I.M. Sechenov First Moscow State Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
57 Years
Max Age
81 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2017-09-01
Completion
2017-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03856242 on ClinicalTrials.gov